{"id":"asunaprevir","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"J05AP06","category":"atc"},{"label":"Active","category":"status"},{"label":"Chronic hepatitis C","category":"indication"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protease Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":295.078,"date":"","count":60,"signal":"Virologic failure","source":"DrugCentral FAERS","actionTaken":"Reported 60 times (LLR=295)"},{"llr":274.165,"date":"","count":53,"signal":"Viral mutation identified","source":"DrugCentral FAERS","actionTaken":"Reported 53 times (LLR=274)"},{"llr":125.07,"date":"","count":29,"signal":"Hepatocellular carcinoma","source":"DrugCentral FAERS","actionTaken":"Reported 29 times (LLR=125)"},{"llr":117.56,"date":"","count":55,"signal":"Alanine aminotransferase increased","source":"DrugCentral FAERS","actionTaken":"Reported 55 times (LLR=118)"},{"llr":107.562,"date":"","count":41,"signal":"Liver injury","source":"DrugCentral FAERS","actionTaken":"Reported 41 times (LLR=108)"},{"llr":78.159,"date":"","count":19,"signal":"Hepatitis B reactivation","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=78)"},{"llr":76.837,"date":"","count":32,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 32 times (LLR=77)"},{"llr":62.45,"date":"","count":11,"signal":"Hepatitis B DNA increased","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=62)"},{"llr":58.219,"date":"","count":27,"signal":"Liver disorder","source":"DrugCentral FAERS","actionTaken":"Reported 27 times (LLR=58)"},{"llr":57.569,"date":"","count":27,"signal":"Ascites","source":"DrugCentral FAERS","actionTaken":"Reported 27 times (LLR=58)"},{"llr":54.334,"date":"","count":33,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=54)"},{"llr":53.808,"date":"","count":24,"signal":"Hepatic failure","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=54)"},{"llr":53.329,"date":"","count":60,"signal":"Pyrexia","source":"DrugCentral FAERS","actionTaken":"Reported 60 times (LLR=53)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ASUNAPREVIR","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:39:24.717825+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:39:30.974851+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ASUNAPREVIR","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:39:31.303157+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Hepatitis C virus serine protease, NS3/NS4A inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:39:32.460716+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105735/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:39:32.105171+00:00"}},"allNames":"sunvepra","offLabel":[],"synonyms":["asunaprevir","BMS-650032","sunvepra"],"timeline":[{"date":"2014-07-04","type":"positive","source":"DrugCentral","milestone":"PMDA approval"}],"aiSummary":"Sunvepra (ASUNAPREVIR) is a small molecule antiviral medication. It is used to treat chronic hepatitis C, a viral infection that causes liver damage. The commercial status of Sunvepra is patented, and it is currently owned by a pharmaceutical company. Key safety considerations include its potential to interact with other medications and its effect on liver function. Sunvepra is not off-patent.","brandName":"Sunvepra","ecosystem":[{"indication":"Chronic hepatitis C","otherDrugs":[{"name":"boceprevir","slug":"boceprevir","company":"Merck Sharp Dohme"},{"name":"daclatasvir","slug":"daclatasvir","company":"Bristol Myers Squibb"},{"name":"dasabuvir","slug":"dasabuvir","company":"Abbvie Inc"},{"name":"elbasvir","slug":"elbasvir","company":"Merck Sharp Dohme"}],"globalPrevalence":58000000}],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Sunvepra (ASUNAPREVIR) is a potent inhibitor of the NS3/4A protease enzyme, which is a key component of the hepatitis C virus replication complex. It binds to the active site of the enzyme, preventing the cleavage of the viral polyprotein and thereby inhibiting viral replication."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4889","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ASUNAPREVIR","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ASUNAPREVIR","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:46:31.832283","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:39:33.770329+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ribavirin","drugSlug":"ribavirin","fdaApproval":"1985-12-31","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"telaprevir","drugSlug":"telaprevir","fdaApproval":"2011-05-23","patentExpiry":"May 30, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"boceprevir","drugSlug":"boceprevir","fdaApproval":"2011-05-13","patentExpiry":"Nov 11, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"simeprevir","drugSlug":"simeprevir","fdaApproval":"2013-11-22","patentExpiry":"Sep 5, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"daclatasvir","drugSlug":"daclatasvir","fdaApproval":"2015-07-24","patentExpiry":"Jun 13, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"sofosbuvir","drugSlug":"sofosbuvir","fdaApproval":"2013-12-06","patentExpiry":"Sep 26, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"dasabuvir","drugSlug":"dasabuvir","fdaApproval":"2014-12-19","relationship":"same-class"},{"drugName":"elbasvir","drugSlug":"elbasvir","fdaApproval":"2016-01-28","relationship":"same-class"},{"drugName":"grazoprevir","drugSlug":"grazoprevir","fdaApproval":"2016-01-28","relationship":"same-class"},{"drugName":"ledipasvir","drugSlug":"ledipasvir","fdaApproval":"2014-10-10","relationship":"same-class"},{"drugName":"ombitasvir","drugSlug":"ombitasvir","fdaApproval":"2014-12-19","relationship":"same-class"},{"drugName":"paritaprevir","drugSlug":"paritaprevir","fdaApproval":"2014-12-19","relationship":"same-class"},{"drugName":"ritonavir","drugSlug":"ritonavir","fdaApproval":"1996-03-01","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"asunaprevir","indications":{"approved":[{"name":"Chronic hepatitis C","source":"DrugCentral","snomedId":128302006,"regulator":"FDA","usPrevalence":2400000,"globalPrevalence":58000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ribavirin","brandName":"ribavirin","genericName":"ribavirin","approvalYear":"1985","relationship":"same-class"},{"drugId":"telaprevir","brandName":"telaprevir","genericName":"telaprevir","approvalYear":"2011","relationship":"same-class"},{"drugId":"boceprevir","brandName":"boceprevir","genericName":"boceprevir","approvalYear":"2011","relationship":"same-class"},{"drugId":"simeprevir","brandName":"simeprevir","genericName":"simeprevir","approvalYear":"2013","relationship":"same-class"},{"drugId":"daclatasvir","brandName":"daclatasvir","genericName":"daclatasvir","approvalYear":"2015","relationship":"same-class"},{"drugId":"sofosbuvir","brandName":"sofosbuvir","genericName":"sofosbuvir","approvalYear":"2013","relationship":"same-class"},{"drugId":"dasabuvir","brandName":"dasabuvir","genericName":"dasabuvir","approvalYear":"2014","relationship":"same-class"},{"drugId":"elbasvir","brandName":"elbasvir","genericName":"elbasvir","approvalYear":"2016","relationship":"same-class"},{"drugId":"grazoprevir","brandName":"grazoprevir","genericName":"grazoprevir","approvalYear":"2016","relationship":"same-class"},{"drugId":"ledipasvir","brandName":"ledipasvir","genericName":"ledipasvir","approvalYear":"2014","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":["Chronic Hepatitis C Infection"],"enrollment":138,"completionDate":"2024-10-31"},{"nctId":"NCT03208322","phase":"","title":"Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2018-11-30","conditions":["Hepatitis C"],"enrollment":0,"completionDate":"2019-02-27"},{"nctId":"NCT03071133","phase":"","title":"Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-01-01","conditions":["Hepatitis C"],"enrollment":344,"completionDate":"2019-01-08"},{"nctId":"NCT02727933","phase":"","title":"Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-03","conditions":["Hepatitis C"],"enrollment":1941,"completionDate":"2020-07-05"},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":["Hepatitis C, Chronic"],"enrollment":300,"completionDate":"2021-08-31"},{"nctId":"NCT02170727","phase":"PHASE3","title":"A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-06-26","conditions":["Hepatitis C Virus"],"enrollment":199,"completionDate":"2015-09-09"},{"nctId":"NCT01995266","phase":"PHASE3","title":"Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02-28","conditions":["Hepatitis C"],"enrollment":218,"completionDate":"2015-07-31"},{"nctId":"NCT02175966","phase":"PHASE2","title":"Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-07-28","conditions":["Hepatitis C"],"enrollment":35,"completionDate":"2015-12-17"},{"nctId":"NCT03794258","phase":"PHASE2","title":"Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection","status":"WITHDRAWN","sponsor":"Humanity & Health Medical Group Limited","startDate":"2019-05-01","conditions":["HCV Infection"],"enrollment":0,"completionDate":"2020-04-30"},{"nctId":"NCT01492504","phase":"","title":"Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-02-07","conditions":["Hepatitis C"],"enrollment":1850,"completionDate":"2018-03-19"},{"nctId":"NCT03887637","phase":"","title":"Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-03-30","conditions":["Chronic Hepatitis C"],"enrollment":180,"completionDate":"2019-09-30"},{"nctId":"NCT03004625","phase":"PHASE3","title":"Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2016-11","conditions":["Hepatitis C"],"enrollment":70,"completionDate":"2018-04"},{"nctId":"NCT02580474","phase":"PHASE4","title":"The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure","status":"COMPLETED","sponsor":"Myeong Jun Song","startDate":"2016-02","conditions":["Hepatitis C"],"enrollment":21,"completionDate":"2018-04"},{"nctId":"NCT02762448","phase":"","title":"Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas","status":"WITHDRAWN","sponsor":"Tainan Municipal Hospital","startDate":"2016-07","conditions":["Hepatitis c"],"enrollment":0,"completionDate":"2018-04-18"},{"nctId":"NCT02124044","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2014-02","conditions":["HIV-HCV"],"enrollment":30,"completionDate":"2016-11"},{"nctId":"NCT02250001","phase":"","title":"Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-09-30","conditions":["Chronic Hepatitis C"],"enrollment":2974,"completionDate":"2017-01-20"},{"nctId":"NCT01455090","phase":"PHASE2","title":"Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-11-30","conditions":["Chronic Hepatitis C"],"enrollment":320,"completionDate":"2015-07-31"},{"nctId":"NCT02496078","phase":"PHASE3","title":"A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-08","conditions":["Hepatitis C"],"enrollment":207,"completionDate":"2017-02"},{"nctId":"NCT02865369","phase":"","title":"Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment","status":"UNKNOWN","sponsor":"Sang Gyune Kim","startDate":"2016-09","conditions":["Chronic Hepatitis C"],"enrollment":103,"completionDate":"2022-12"},{"nctId":"NCT01888900","phase":"PHASE2","title":"New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2013-05","conditions":["Cirrhosis","Chronic Hepatitis C","Hepatitis C","Hepatitis C, Chronic"],"enrollment":35,"completionDate":"2015-11"},{"nctId":"NCT02107365","phase":"PHASE2","title":"Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2013-11","conditions":["Hepatitis C Virus Genotype 4 Infection"],"enrollment":60,"completionDate":"2015-04"},{"nctId":"NCT02292966","phase":"PHASE4","title":"Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism","status":"WITHDRAWN","sponsor":"Kirby Institute","startDate":"2015-07","conditions":["Hepatitis C, Chronic"],"enrollment":0,"completionDate":"2016-06"},{"nctId":"NCT01428063","phase":"PHASE2","title":"Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-09","conditions":["Hepatitis C Virus Infection"],"enrollment":276,"completionDate":"2014-12"},{"nctId":"NCT02098616","phase":"NA","title":"Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus","status":"COMPLETED","sponsor":"Timothy Morgan, MD","startDate":"2014-07","conditions":["Hepatitis C"],"enrollment":25,"completionDate":"2016-02"},{"nctId":"NCT02470858","phase":"PHASE2","title":"Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":["Chronic Hepatitis C Infection"],"enrollment":18,"completionDate":"2015-12"},{"nctId":"NCT02309450","phase":"PHASE2","title":"Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-12","conditions":["Hepatitis C Virus Genotype 4 Infection"],"enrollment":0,"completionDate":"2016-08"},{"nctId":"NCT02639585","phase":"PHASE4","title":"Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2015-12","conditions":["Hepatitis C, Chronic"],"enrollment":32,"completionDate":"2017-06"},{"nctId":"NCT01979939","phase":"PHASE3","title":"UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-12","conditions":["Hepatitis C"],"enrollment":416,"completionDate":"2014-11"},{"nctId":"NCT02282709","phase":"PHASE3","title":"Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2014-02","conditions":["Chronic Hepatitis C"],"enrollment":12,"completionDate":"2015-07"},{"nctId":"NCT01309932","phase":"PHASE2","title":"Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-03","conditions":["Hepatitis C"],"enrollment":165,"completionDate":"2014-09"},{"nctId":"NCT01573351","phase":"PHASE3","title":"Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":["Hepatitis C Virus"],"enrollment":398,"completionDate":"2013-12"},{"nctId":"NCT01718145","phase":"PHASE3","title":"A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-11","conditions":["Hepatitis C Virus Infection"],"enrollment":258,"completionDate":"2014-12"},{"nctId":"NCT01051414","phase":"PHASE2","title":"An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-04","conditions":["Hepatitis C Infection"],"enrollment":43,"completionDate":"2012-05"},{"nctId":"NCT01030432","phase":"PHASE2","title":"Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-02","conditions":["Hepatitis C Virus"],"enrollment":285,"completionDate":"2012-10"},{"nctId":"NCT01973049","phase":"PHASE3","title":"UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-12","conditions":["Hepatitis C"],"enrollment":202,"completionDate":"2014-11"},{"nctId":"NCT01795911","phase":"PHASE2","title":"Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03","conditions":["Hepatitis C"],"enrollment":165,"completionDate":"2014-09"},{"nctId":"NCT01497834","phase":"PHASE3","title":"A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-01","conditions":["Hepatitis C"],"enrollment":224,"completionDate":"2013-06"},{"nctId":"NCT01581203","phase":"PHASE3","title":"Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":["Hepatitis C Virus"],"enrollment":748,"completionDate":"2014-09"},{"nctId":"NCT01012895","phase":"PHASE2","title":"Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":["Chronic Hepatitis C"],"enrollment":215,"completionDate":"2014-02"},{"nctId":"NCT02123654","phase":"PHASE3","title":"UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":["Hepatitis C Virus Infection"],"enrollment":297,"completionDate":"2015-08"},{"nctId":"NCT02323594","phase":"PHASE1","title":"A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-12","conditions":["Hepatitis C Infection"],"enrollment":88,"completionDate":"2015-02"},{"nctId":"NCT02175602","phase":"PHASE1","title":"Study of Drug Combination on Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-06","conditions":["Hepatitis C Infection"],"enrollment":41,"completionDate":""},{"nctId":"NCT02095860","phase":"PHASE1","title":"Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":["Hepatitis C"],"enrollment":24,"completionDate":"2014-05"},{"nctId":"NCT01725542","phase":"PHASE2","title":"Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-12","conditions":["HCV-HIV Co-Infection"],"enrollment":75,"completionDate":"2014-06"},{"nctId":"NCT02103569","phase":"PHASE1","title":"Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":["Hepatitis C"],"enrollment":20,"completionDate":"2014-07"},{"nctId":"NCT02104843","phase":"PHASE1","title":"Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":["Hepatitis C"],"enrollment":18,"completionDate":"2014-05"},{"nctId":"NCT02108639","phase":"PHASE1","title":"To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":["Hepatitis C"],"enrollment":41,"completionDate":"2014-06"},{"nctId":"NCT02045966","phase":"PHASE1","title":"Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":["Hepatitis C"],"enrollment":16,"completionDate":"2014-04"},{"nctId":"NCT02045693","phase":"PHASE1","title":"Drug Interaction & Methadone & Buprenorphine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":["Hepatitis C"],"enrollment":32,"completionDate":"2014-04"},{"nctId":"NCT01886599","phase":"PHASE1","title":"Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-11","conditions":["Hepatitis C"],"enrollment":48,"completionDate":"2013-02"},{"nctId":"NCT01019070","phase":"PHASE1","title":"Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":["Hepatic Insufficiency"],"enrollment":28,"completionDate":"2011-08"},{"nctId":"NCT00722358","phase":"PHASE2","title":"A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-12","conditions":["Chronic Hepatitis C"],"enrollment":15,"completionDate":"2009-12"},{"nctId":"NCT01063023","phase":"PHASE1","title":"Drug Interaction Oral Contraceptive Pill (OCP)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-01","conditions":["Hepatitis C Virus"],"enrollment":20,"completionDate":"2010-06"},{"nctId":"NCT00904059","phase":"PHASE1","title":"Drug-Drug Interaction Study in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-05","conditions":["Hepatitis C"],"enrollment":28,"completionDate":"2009-07"},{"nctId":"NCT00559247","phase":"PHASE1,PHASE2","title":"A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-01","conditions":["Chronic Hepatitis C"],"enrollment":24,"completionDate":"2008-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"016060","UNII":"S9X0KRJ00S","CHEBI":"CHEBI:134723","INN_ID":"9472","RXNORM":"1652103","UMLSCUI":"C3491974","chemblId":"CHEMBL2105735","ChEMBL_ID":"CHEMBL2105735","KEGG_DRUG":"D10093","DRUGBANK_ID":"DB11586","PDB_CHEM_ID":" 2R9","PUBCHEM_CID":"16076883","SNOMEDCT_US":"715390003","IUPHAR_LIGAND_ID":"10882","MESH_SUPPLEMENTAL_RECORD_UI":"C571889"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"20.0 hours","clearance":"11.78 mL/min/kg","fractionUnbound":"0.012%","volumeOfDistribution":"2.77 L/kg"},"publicationCount":435,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J05AP06","allCodes":["J05AP06","J05AP58"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"2014","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:39:33.770329+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}